Efficacy and safety of CD19-specific CAR-T cell-based therapy in secondary central nervous system lymphoma

Encouraging response has been achieved in relapsed/refractory (R/R) B-cell lymphoma treated by chimeric antigen receptor T (CAR-T) cells. The efficacy and safety of CAR-T cells in central nervous system lymphoma (CNSL) are still elusive. Here, we retrospectively analyzed 15 patients with R/R seconda...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Huanxin, Yan, Zhiling, Wang, Ying, Qi, Yuekun, Hu, Yongxian, Li, Ping, Cao, Jiang, Zhang, Meng, Xiao, Xia, Shi, Ming, Xia, Jieyun, Ma, Sha, Qiao, Jianlin, Li, Hujun, Pan, Bin, Qi, Kunming, Cheng, Hai, Sun, Haiying, Zhu, Feng, Sang, Wei, Li, Depeng, Li, Zhenyu, Zheng, Junnian, Zhao, Mingfeng, Liang, Aibin, Huang, He, Xu, Kailin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9437350/
https://www.ncbi.nlm.nih.gov/pubmed/36059496
http://dx.doi.org/10.3389/fimmu.2022.965224

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9437350/
https://www.ncbi.nlm.nih.gov/pubmed/36059496
http://dx.doi.org/10.3389/fimmu.2022.965224

Ejemplares similares